USF issued patent for technology to improve treatment for neurodegenerative diseases

Umbilical blood cells and sugar-alcohol compound combined help deliver treatment past the blood-brain barrier

Tampa, FL (July 8, 2010) — The University of South Florida’s Department of Neurosurgery and Brain Repair has been granted a patent for a cell transplantation procedure combining human umbilical cord blood (HUCB) cells and a sugar-alcohol compound called mannitol that may make a big difference in treating life-threatening neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and stroke, among others.

The technology administers the neuroprotective effect of umbilical cord blood cells along with mannitol to permeabilize the blood-brain barrier, allowing for the increased entry of therapeutic growth factors. Saneron CCEL Therapeutics, Inc., a biotechnology R&D USF spin-out company located at the Tampa Bay Technology Incubator, has licensed the technology.

Approximately 750,000 strokes occur every year in the United States, and nearly one third of them are fatal, said Saneron’s President and Chief Operating Officer Nicole Kuzmin-Nichols, MBA. “Given the devastating effects of stroke, it is imperative that we develop new therapies to minimize damage to the brain as well as repair the damage. We are excited about this new technology and its potential to help us develop a variety of new products and therapies to do just that.”

While transplanted HUCB cells may benefit several neurological diseases, getting them past the blood-brain-barrier has presented a problem. The blood-brain barrier separates circulating blood and cerebral spinal fluid in the central nervous system. The newly patented technology is based on mannitol acting as a blood-brain barrier permeabilizer to help get the therapeutic substances secreted by HUCB cells past the blood-brain barrier and into the central nervous system. Mannitol, which temporarily shrinks the tight cells that make up the barrier, allows HUCB cells, via their secreted factors, to reach the site of injury or disease.

Human umbilical cord blood contains a high percentage of stem cells that when intravenously administered can survive and differentiate into neurons in the damaged brain.  Equally appealing is their ability to secrete beneficial molecules that potentially promote behavioral recovery, said Dr. Cesar Borlongan, co-inventor and a USF neuroscientist and professor and consultant for Saneron. “Because the blood-brain barrier regulates the entry of many blood-borne substances into the brain, it may exclude potentially therapeutic substances.”

“The use of stem cell therapy as a treatment for neurodegenerative disorders shows exciting promise, though several hurdles must be overcome and getting the cells correctly positioned is one of those,” said Kuzmin-Nichols. “This technology provides the means to deliver the HUCB cells directly to the damaged brain to maximize their effect.”

About USF Center of Excellence for Aging and Brain Repair

The mission of the University of South Florida Center of Excellence for Aging and Brain Repair is to develop new therapeutic strategies to promote repair and regeneration of aging and diseased brain. Building on a foundation of excellence in basic and clinical research, the Center focuses on translating innovative ideas into industrial partnerships, educational and clinical services to address key needs of the community and those suffering from brain injury and disease.

About Saneron CCEL Therapeutics, Inc.

Saneron is a biotechnology R&D company, focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases, which lack adequate treatment options. Saneron, a University of South Florida spin-out company is located at the Tampa Bay Technology Incubator. An affiliate of Cryo-Cell International, Inc., Saneron is committed to providing readily available, non-controversial stem cells for cellular therapies and has patented and patent-pending technology relating to our platform technology of umbilical cord blood and Sertoli cells.

For further information, please contact:

Saneron CCEL Therapeutics Inc.,
Nicole Kuzmin-Nichols, MBA
3802 Spectrum Blvd., Suite 147
Tampa, FL 33612
Phone: 813-977-7664 x2
nkn@saneron-ccel.com

Be Sociable, Share!